Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation
The road of acceptance of oncologic thermotherapy/hyperthermia as a synergistic modality in combination with standard oncologic therapies is still bumpy. This is partially due to the lack of level I evidence from international, multicentric, randomized clinical trials including large patient numbers...
Saved in:
Other Authors: | , , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_87516 | ||
005 | 20220706 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20220706s2022 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-4531-8 | ||
020 | |a 9783036545325 | ||
020 | |a 9783036545318 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-4531-8 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
072 | 7 | |a MJCL |2 bicssc | |
100 | 1 | |a Bodis, Stephan |4 edt | |
700 | 1 | |a Ghadjar, Pirus |4 edt | |
700 | 1 | |a Van Rhoon, Gerard C. |4 edt | |
700 | 1 | |a Bodis, Stephan |4 oth | |
700 | 1 | |a Ghadjar, Pirus |4 oth | |
700 | 1 | |a Van Rhoon, Gerard C. |4 oth | |
245 | 1 | 0 | |a Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
300 | |a 1 electronic resource (346 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a The road of acceptance of oncologic thermotherapy/hyperthermia as a synergistic modality in combination with standard oncologic therapies is still bumpy. This is partially due to the lack of level I evidence from international, multicentric, randomized clinical trials including large patient numbers and a long term follow-up. Therefore we need more level I EVIDENCE from clinical trials, we need HARMONISATION and global acceptance for existing technologies and a common language understood by all stakeholders and we need INNOVATION in the fields of biology, clinics and technology to move thermotherapy/hyperthermia forward. This is the main focus of this reprint. In this reprintyou find carefully selected and peer-reviewed contributions from Africa, America, Asia, and Europe. The published papers from leading scientists from all over the world covering a broad range of timely research topics might also help to strengthen thermotherapy on a global level. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
650 | 7 | |a Oncology |2 bicssc | |
653 | |a perfusion estimation | ||
653 | |a temperature monitoring | ||
653 | |a conductivity reconstruction | ||
653 | |a systems medicine | ||
653 | |a immune system in silico | ||
653 | |a perceptron | ||
653 | |a antigen pattern | ||
653 | |a danger signal | ||
653 | |a fractionation | ||
653 | |a immune response | ||
653 | |a head and neck cancer | ||
653 | |a hyperthermia | ||
653 | |a reirradiation | ||
653 | |a treatment outcome | ||
653 | |a hyperthermia treatment planning | ||
653 | |a adaptive planning | ||
653 | |a temperature optimization | ||
653 | |a low-middle-income group countries | ||
653 | |a cancer | ||
653 | |a radiotherapy | ||
653 | |a chemotherapy | ||
653 | |a recurrent breast cancers | ||
653 | |a cervical cancer | ||
653 | |a head and neck cancers | ||
653 | |a cost-effective | ||
653 | |a meta-analysis | ||
653 | |a intensity-modulated radiotherapy | ||
653 | |a prostate cancer | ||
653 | |a thermal dose | ||
653 | |a thermometric parameters | ||
653 | |a preclinical data | ||
653 | |a clinical evidence | ||
653 | |a modulated electro-hyperthermia | ||
653 | |a abscopal effect | ||
653 | |a locally advanced cervical cancer | ||
653 | |a resource-constrained setting | ||
653 | |a radiosensitiser | ||
653 | |a rectal cancer | ||
653 | |a chemoradiotherapy | ||
653 | |a tumour control | ||
653 | |a loco-regional hyperthermia | ||
653 | |a oncology | ||
653 | |a cellular selection | ||
653 | |a bioelectromagnetics | ||
653 | |a complexity | ||
653 | |a immune-effects | ||
653 | |a moderate hyperthermia | ||
653 | |a deep hyperthermia | ||
653 | |a radiative hyperthermia | ||
653 | |a patterns of care | ||
653 | |a reimbursement | ||
653 | |a regional hyperthermia | ||
653 | |a neoadjuvant chemoradiation | ||
653 | |a survival | ||
653 | |a induced | ||
653 | |a brachytherapy | ||
653 | |a prostatic neoplasms | ||
653 | |a interstitial hyperthermia | ||
653 | |a treatment plan optimization | ||
653 | |a prostate | ||
653 | |a thermoradiotherapy | ||
653 | |a linear quadratic model | ||
653 | |a biological modeling | ||
653 | |a thermal dosimetry | ||
653 | |a hypoxia | ||
653 | |a radiation therapy | ||
653 | |a reoxygenation | ||
653 | |a perfusion | ||
653 | |a oxygen consumption rate | ||
653 | |a local tumor control | ||
653 | |a biomarker | ||
653 | |a immune phenotype | ||
653 | |a hyperthermia treatment sequence | ||
653 | |a breast cancer | ||
653 | |a immune checkpoint molecules | ||
653 | |a dendritic cell activation | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5714 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/87516 |7 0 |z DOAB: description of the publication |